The results showed that the combination of SHP099 and vemurafenib significantly reduced the phosphorylation levels of SHP2, MEK, ERK and significantly enhanced the tumor suppressive effect of vemurafenib compared to that of SHP099 or vemurafenib alone (Figure 3A). Here, MAP2K7 is linked to neoplasm.